1. Carnot P, Deflandre C. Sur l'activite cytopoietique du sang et des organs regeneres au cours des regeneration du sang. C R Acad Sci (Paris) 1906; 143:432-435.

2. Viault F. Sur la quantite d'oxygen contenue dans le sang des animaux des hauts pleateaux de L'Amerique du Sud. C R Acad Sci (Paris) 1891; 112:295-298.

3. Fung MC, Hapel AJ, Ymer S, et al. Molecular cloning of cDNA for murine inter-leukin-3. Nature 1984; 307(5948):233-237.

4. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14:213-222.

5. Pluznik DH, Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol 1965; 66(3):319-324.

6. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44(3):287-299.

7. Stanley ER, Heard PM. Factors regulating macrophage production and growth purification and some properties of the colony stimulating factor from medium conditioned by mouse L neoplastic fibroblast cells. J Biol Chem 1977; 252(12):4305-4312.

8. Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony stimulating factor from mouse lung conditioned medium. J Biol Chem 1977; 252(6): 1998-2003.

Nicola NA, Metcalf D, Matsumoto M, et al. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells identification as granulocyte colony stimulating factor. J Biol Chem 1983; 258(14):9017-9023. Kawasaki ES, Ladner MB, Wang AM, et al. Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor Csf-1. Science 1985; 230(4723):291-296.

Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and complementary DNA clones of human erythropoietin. Nature 1985; 313(6005):806-810.

Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82(22):7580-7584.

Wong GG, Witek JS, Temple PA, et al. Human granulocyte-macrophage colony-

stimulating factor molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228(4701):810-815.

Lee F, Yokota T, Otsuka T, et al. Isolation of complementary DNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proc Natl Acad Sci U S A 1985; 82(13):4360-7364.

Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-

stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232

Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319(6052):415-418. Yang YC, Ciarletta AB, Temple PA, et al. Human interleukin 3 multi-colony-stimulating factor identification by expression cloning of a novel hematopoietic growth factor related to murine interleukin 3. Cell 1986; 47(1):3-10. Kinashi T, Harada N, Severinson E, et al. Cloning of complementary DNA encoding T cell replacing factor and identity with B cell growth factor II. Nature 1986; 324 (6092):70-73.

Tominaga A, Takahashi T, Kikuchi Y, et al. Role of carbohydrate moiety of IL-5 effect of tunicamycin on the glycosylation of IL-5 and the biologic activity of deglycosylated IL-5. J Immunol 1990; 144(4):1345-1352.

Santhanam U, Ghrayer J, Sehgal PB, et al. Post-translational modifications of human interleukin-6. Arch Biochem Biophys 1989; 274(1):161-170.

Namen AE, Schmierer AE, March CJ, et al. B cell precursor growth-promoting activity purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988; 167(3):988-1002.

Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 1985; 82(5):1526-1530.

Das SK, Stanley ER. Structure function studies of a colony stimulating factor CSF-1. J Biol Chem 1982; 257(22):13679-13684.

Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver—conditioned medium. Cell 1990; 63(1):195-201.

Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985; 116(6):2293-2299.

Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(suppl 3):3-13.

Metcalf D. Hematopoietic cytokines. Blood 2008; 111(2):485-491.

Molineux G, Foote MA, Elliott SG. Erythropoietins and erythropoiesis: molecular, cellular, preclinical, and clinical biology. In: Molineux G, Foote MA, Elliott SG, eds.

Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical

Biology. Cambridge: Birkhaeuser Publishing Limited, 2003:i-xi, 1-269.

Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first

10 years. Blood 1996; 88(6):1907-1929.

Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors 2004; 22(4):225-231.

31. Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93(8):2491-2501.

32. Young JD, Crawford J, Gordon M, et al. Pharmacokinetics (pk) of recombinant methionyl human stem cell factor (SCF) in patients (pts) with lung or breast cancer in phase I trials. Proceedings of the American Association for Cancer Research Annual Meeting 1993; 34:217.

33. Lynch DH, Jacobs C, Dupont D, et al. Pharmacokinetic parameters of recombinant mast cell growth factor (rMGF). Lymphokine Cytokine Res 1992; 11(5):233-243.

34. Levesque J-P, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104(1):65-72.

35. Duarte RF, Franf DA. The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma 2002; 43(6):1179-1187.

36. Metcalf D, Begley CG, Johnson GR, et al. Biological properties in-vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67(1):37-45.

37. Kenny PA, McDonald PJ, Finlay-Jones JJ. The effect of cytokines on bactericidal activity of murine neutrophils. FEMS Immunol Med Microbiol 1993; 7(3):271-279.

38. Kapp A, Zeck-Kapp G, Danner M, et al. Human granulocyte-macrophage colony stimulating factor an effective direct activator of human polymorphonuclear neu-trophilic granulocytes. J Invest Dermatol 1988; 91(1):49-55.

39. Jones TC. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med Oncol 1996; 13(3):141-147.

40. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in-vitro. J Clin Invest 1990; 85(3):955-961.

41. Liljefors M, Nilsson B, Mellstedt H, et al. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2008; 57(3):379-388.

42. Cebon JS, Bury RW, Lieschke GJ, et al. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer 1990; 26(10):1064-1069.

43. Mueller CE, Mukodzi S, Reddemann H. Relationships of cytokine (GM-CSF) serum concentration to blood cell count and the inflammatory parameters in children with malignant diseases. Pediatr Hematol Oncol 1999; 16(6):509-518.

44. Stute N, Furman WL, Schell M, et al. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 1995; 84(7):824-828.

45. Cebon J, Dempsey P, Fox R, et al. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood 1988; 72(4):1340-1347.

46. Stanley ER, Hansen G, Woodcock J, et al. Colony stimulating factor and the regulation of granulopoiesis and macrophage production. Fed Proc 1975; 34(13):2272-2278.

47. Fixe P, Praloran V. M-CSF: haematopoietic growth factor or inflammatory cytokine? Cytokine 1998; 10(1):32-37.

48. Ai-Aql ZS, Alagl AS, Graves DT, et al. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008; 87(2):107-118.

49. Shimada-Hiratsuka M, Naito M, Kaizu C, et al. Defective macrophage recruitment and clearance of apoptotic cells in the uterus of osteopetrotic mutant mice lacking macrophage colony-stimulating factor (M-CSF). J Submicrosc Cytol Pathol 2000; 32(2):297-307.

50. Yagihashi A, Sekiya T, Suzuki S. Macrophage colony stimulating factor (M-CSF) protects spiral ganglion neurons following auditory nerve injury: morphological and functional evidence. Exp Neurol 2005; 192(1):167-177.

51. Murase S-I, Hayashi Y. Expression pattern and neurotrophic role of the c-fms proto-oncogene M-CSF receptor in rodent Purkinje cells. J Neurosci 1998; 15:10481-10492.

Tkachuk M, Gisler RH. The promoter of macrophage colony-stimulating factor receptor is active in astrocytes. Neurosci Lett 1997; 225(2):121-125. Uemura Y, Kobayashi M, Nakata H, et al. Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways. Int J Mol Med 2006; 18(2):365-373.

Pederson L, Winding B, Foged NT, et al. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999; 59(22):5849-5855.

Takagi A, Takeda S, Matsuoka K, et al. Macrophage colony-stimulating factor (M-CSF) production in vivo and in vitro in gynecologic malignancies. Int J Clin Oncol 1999; 4(3):142-147.

Ramakrishnan S, Xu FJ, Brandt SJ, et al. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 1989; 83(3):921-926.

Tanaka H, Takama H, Arai Y, et al. Pharmacokinetics of pegylated recombinant human megakaryocyte growth and development factor in healthy volunteers and patients with hematological disorders. Eur J Haematol 2004; 73(4):269-279. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999; 106(2):345-356.

Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmaco-kinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001; 298(2):820-824.

Agoram B, Molineux G, Jang G, et al. Effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: a minor role of erythropoietin receptor-mediated pathways? Nephrol Dial Transplant 2006(4):303-304. Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74(4):1303-1307.

Bartocci A, Mastrogiannis DS, Migliorati G, et al. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A 1987; 84(17):6179-6183.

Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony stimulating factor on normal mouse hemopoietic cells. J Cell Physiol 1983; 116(2):198-206. Lord BI. Myeloid cell kinetics in response to haemopoietic growth factors. Baillieres Clin Haematol 1992; 5(3):533-550.

Lord BI, Molineux G, Pojda Z, et al. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or gran-ulocyte-macrophage CSF in vivo. Blood 1991; 77(10):2154-2159. Takamatsu Y, Simmons PJ, Moore RJ, et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but it not responsible for hematopoietic progenitor cell mobilization. Blood 1998; 92(9):3465-373.

Purton LE, Lee MY, Torok-Storb B. Normal human peripheral blood mononuclear cells mobilized with granulocyte colony-stimulating factor have increased osteo-clastogenic potential compared to nonmobilized blood. Blood 1996; 87(5):1802-1808. Lee MY, Fukunaga R, Lee TJ, et al. Bone modulation in sustained hematopoietic stimulation in mice. Blood 1991; 77(10):2135-2141.

Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56(6):809-813.

Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1(8587):667-672. Morstyn G, Campbell L, Duhrsen U, et al. Clinical studies with granulocyte colony stimulating factor G-Csf in patients receiving cytotoxic chemotherapy. Behring Inst Mitt 1988; 83:234-239.

72. Roskos L, Cheung E, Vincent M, et al. Pharmacology of Filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter TM, Foote M, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. 2nd ed. New York: Marcel Dekker, 1998:51-72.

73. Terashi K, Oka M, Ohdo S, et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999; 43(1):21-24.

74. Holmes FA, Jones SE, O'Shaughnessy J, et al. Once-per-cycle pegylated filgrastim (SD/01) is as effective and safe as daily filgrastim in reducing chemotherapy-induced neutropenia over multiple cycles of therapy. Breast Cancer Res Treat 2000; 64(1):89.

75. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18(13):2522-2528.

76. Molineux G, Kinstler O, Briddell B, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27(12):1724-1734.

77. Roskos LK, Yang B, Schwab G, et al. A cytokinetic model describes the gran-ulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers. Clin Pharmacol Ther 1999; 65(2):196.

78. Green M. A single, fixed-dose of Pegfilgrastim given once-per-chemotherapy cycle is as effective as daily Filgrastim in the management of neutropenia in high-risk breast cancer. Eur J Cancer 2001; 37(suppl 6):S146-S147.

79. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin results of a combined phase I and II clinical trial. N Engl J Med 1987; 316(2):73-78.

80. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141(1):14-31.

81. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107(5):1892-1895.

82. Sun CH, Ward HJ, Paul WL, et al. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989; 321(3):151-157.

83. Wide L, Bengtsson C, Birgegard G. Circadian rhythm of erythropoietin in human serum. Br J Haematol 1989; 72(1):85-90.

84. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57(5):411-418.

85. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease the case for subcutaneous administration. J Am Soc Nephrol 1992; 2(9):1405-1416.

86. Jumbe NL, Rossi G, Heatherington AC. The science of erythropoiesis: quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamic (PD) modeling. Blood 2002; 100:9b.

87. Macdougall IC. Optimizing the use of erythropoietic agents—pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17(suppl 5):66-70.

88. Topf J. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008; 9(5):839-849.

89. Wiecek A, Macdougall IC, Mikhail A, et al. Long-term safety, tolerability, and pharmacodynamics of hematide (TM) a synthetic peptide-based erythropoiesis stimulating agent in a phase II, multi-dose study in patients with chronic kidney disease. Nephrol Dial Transplant 2006; 21(4):155.

90. Keleman E, Cserhati I, Tanos B. Demonstration of some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958; 20(6):350-355.

91. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombo-poietin. J Biochem 1995; 118(1):229-236.

92. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a mega-karyocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77(7):1117-11124.

93. De Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369(6481):533-538.

94. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine throm-bopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369 (6481):565-568.

95. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994; 91(23):11104-11108.

96. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99(7):2599-2602.

97. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98(12):3241-3248.

98. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109(11):4607-4616.

99. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000; 95(8):2514-2522.

100. Sola MC, Christensen RD, Hutson AD, et al. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000; 47(2):208-214.

101. Kuter D. Thrombopoietin factors. In: Morstyn G, Foote M, Lieschke G, eds. Cancer Drug Discovery and Development Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totawa, NJ: Humana Press, 2004:125-152.

102. Begley CG. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand). Thromb Haemost 1997; 78(1):42-46.

103. Kuter D, Bussel JB, Aledort LM, et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune throm-bocytopenic purpura (ITP). Blood 2004; 104(11 pt 1):148a

104. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(suppl 1):3-10.

105. Streeter PR, Kahn LE, Joy WD, et al. Progenipoietin-G, a multifunctional agonist of human flt-3 and G-CSF receptors. Blood 1997; 90(suppl 1, part 1):57a.

0 0

Post a comment